The Dual Role of Macrophages in MIRI and MI by Immunity and Inflammation: Damage, Repair, Crosstalk, and Therapy.

IF 4.2 3区 医学 Q2 CELL BIOLOGY
Mediators of Inflammation Pub Date : 2025-10-06 eCollection Date: 2025-01-01 DOI:10.1155/mi/9912957
Zhilin Miao, Yamki Leung, Yuqing Fu, Li Luo, Quan Liu, Jianbo Liao, Jiatang Xu, Qingyang Song, Suiqing Huang, Zhongkai Wu
{"title":"The Dual Role of Macrophages in MIRI and MI by Immunity and Inflammation: Damage, Repair, Crosstalk, and Therapy.","authors":"Zhilin Miao, Yamki Leung, Yuqing Fu, Li Luo, Quan Liu, Jianbo Liao, Jiatang Xu, Qingyang Song, Suiqing Huang, Zhongkai Wu","doi":"10.1155/mi/9912957","DOIUrl":null,"url":null,"abstract":"<p><p>The global prevalence of coronary artery disease (CAD) continues to escalate globally. A substantial proportion of CAD patients develop myocardial ischemic injury or myocardial infarction (MI), while reperfusion therapy paradoxically induces myocardial ischemia/reperfusion injury (MIRI). Tissue-resident and recruited macrophages critically orchestrate cardiac inflammation resolution and repair-remodeling processes. Pathogenically, MIRI features early explosive inflammation with secondary reperfusion injury, whereas MI progresses from acute inflammation to reparative fibrosis. We highlight two pivotal macrophage subsets-C─C chemokine receptor type 2 (CCR2)<sup>high</sup> macrophages dominating early MI phases and triggering receptor expressed on myeloid cells 2 (TREM2)<sup>high</sup> macrophages prevailing in late stages-exploring their distinct roles in both MI and MIRI. This includes examining macrophage crosstalk with neutrophils and other immune-inflammatory cells. Finally, we discuss macrophage-targeted therapies encompassing anti-inflammatory modulation, exosome-mediated delivery, and stem cell interventions to mitigate cardiac injury progression.</p>","PeriodicalId":18371,"journal":{"name":"Mediators of Inflammation","volume":"2025 ","pages":"9912957"},"PeriodicalIF":4.2000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517984/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediators of Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/mi/9912957","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The global prevalence of coronary artery disease (CAD) continues to escalate globally. A substantial proportion of CAD patients develop myocardial ischemic injury or myocardial infarction (MI), while reperfusion therapy paradoxically induces myocardial ischemia/reperfusion injury (MIRI). Tissue-resident and recruited macrophages critically orchestrate cardiac inflammation resolution and repair-remodeling processes. Pathogenically, MIRI features early explosive inflammation with secondary reperfusion injury, whereas MI progresses from acute inflammation to reparative fibrosis. We highlight two pivotal macrophage subsets-C─C chemokine receptor type 2 (CCR2)high macrophages dominating early MI phases and triggering receptor expressed on myeloid cells 2 (TREM2)high macrophages prevailing in late stages-exploring their distinct roles in both MI and MIRI. This includes examining macrophage crosstalk with neutrophils and other immune-inflammatory cells. Finally, we discuss macrophage-targeted therapies encompassing anti-inflammatory modulation, exosome-mediated delivery, and stem cell interventions to mitigate cardiac injury progression.

Abstract Image

Abstract Image

Abstract Image

巨噬细胞通过免疫和炎症在MIRI和MI中的双重作用:损伤、修复、串扰和治疗。
冠状动脉疾病(CAD)的全球患病率在全球范围内持续上升。相当比例的CAD患者发生心肌缺血损伤或心肌梗死(MI),而再灌注治疗却矛盾地诱发心肌缺血/再灌注损伤(MIRI)。组织常驻和招募的巨噬细胞对心脏炎症的消退和修复重塑过程至关重要。在病理上,MIRI表现为早期爆炸性炎症伴继发性再灌注损伤,而MI则从急性炎症发展为修复性纤维化。我们强调了两个关键的巨噬细胞亚群——C─C趋化因子受体2型(CCR2)高巨噬细胞主导心肌梗死早期阶段和触发受体表达于髓样细胞2 (TREM2)高巨噬细胞主导晚期阶段——探索它们在心肌梗死和MIRI中的独特作用。这包括检查巨噬细胞与中性粒细胞和其他免疫炎症细胞的串扰。最后,我们讨论了巨噬细胞靶向治疗,包括抗炎调节、外泌体介导的递送和干细胞干预,以减轻心脏损伤的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Mediators of Inflammation
Mediators of Inflammation 医学-免疫学
CiteScore
8.70
自引率
0.00%
发文量
202
审稿时长
4 months
期刊介绍: Mediators of Inflammation is a peer-reviewed, Open Access journal that publishes original research and review articles on all types of inflammatory mediators, including cytokines, histamine, bradykinin, prostaglandins, leukotrienes, PAF, biological response modifiers and the family of cell adhesion-promoting molecules.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信